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Throughout this report, the following abbreviations and symbols are used: 
 
ANOVA Analysis of variance 
CAD Collision Gas  
CUR  Curtain Gas 
CRM Certified reference material 
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GS2 Ion Source gas 2 
HLB Hydrophilic-lipophilic balance 
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voltage 
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JRC Joint Research Centre 
 
 
 
LC Liquid chromatography 
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NSAID Non-steroidal anti-inflammatory 
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PPG Polypropylene glycol 
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SD Standard deviation 
SPE Solid-phase extraction 
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UHPLC Ultra-high-pressure liquid 
chromatography 
WFD Water Framework Directive 
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1 Introduction 
 
Diclofenac chemical structure: 
 
 
Chemical property data 
Formula C14H11Cl2NO2  
Molecular mass 296.148 g/mol 
CAS number  15307-86-5 
Systematic IUPAC name 2-(2-(2,6-dichlorophenylamino)phenyl)acetic acid 
 
Since the pharmaceutical market has been growing in recent decades, the issue of 
pharmaceuticals in the environment gives rise to increasing public concern because various 
types of medicinal products (hormones, anti-cancer drugs, antidepressants, antibiotics, etc.) 
have been detected in various environmental compartments, such as surface water, 
groundwater, soil, air, and biota. Although it is unlikely that the concentrations of 
pharmaceutical residues in the environment could provoke direct toxicological effects in 
human beings, the long-term (chronic) exposure has been reported to have effects on 
wildlife. The two most prominent and well-documented cases of direct ecotoxicological 
effects of pharmaceutical residues in wildlife address the presence of ethinylestradiol in 
water bodies, which causes the feminisation of male fish (Caldwell et al., 2008; Kidd et al., 
2007), and the use of diclofenac. 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) taken or applied to reduce 
inflammation and used as an analgesic to reduce certain types of pain. It is supplied as or 
contained in medication under a variety of trade names, and is also administered to livestock 
as an anti-inflammatory medication.  
Diclofenac has been found to directly affect wildlife as a consequence of its widespread use 
as a veterinary drug for cattle. Tens of millions of vultures in India died as a result of feeding 
on the corpses of cows treated with diclofenac (Oaks et al., 2004; Risebrough, 2004). 
In the first review of the list of priority substances (PS) under the European Water 
Framework Directive (WFD), the Commission legislative proposal introduced an 
environmental quality standard (EQS) for diclofenac in the aquatic environment. The annual 
average EQS value (AA-EQS) for diclofenac was set at 0.1 µg/l in inland surface waters 
(including rivers, lakes and related artificial or heavily modified water bodies), and at 0.01 
µg/l in other (coastal) surface waters. Diclofenac has been put on the newly introduced 
“watch list” mechanism to collect European Union-wide monitoring data (EU, 2013).  
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The analytical method reported in this report is based on solid-phase extraction (SPE) using 
a universal reversed-phase sorbent (HLB: hydrophilic-lipophilic balance) followed by ultra-
high-pressure liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) 
analysis. The procedure has been fully characterised in terms of linearity, working range, 
selectivity, precision, repeatability, trueness and uncertainty. 
The objective of this method validation exercise is to contribute to the chemical analysis of 
diclofenac in the aquatic environment in compliance with the first watch list exercise for the 
implementation of the Water Framework Directive (WFD). 
2 Materials and methods  
2.1 Chemicals  
2.1.1 Standards 
Diclofenac sodium salt, CAS 15307-79-6, batch 30266, purity 99.5%, expiry date March 11, 
2017, Sigma Aldrich, MO (USA). 
Diclofenac-(Acetophenyl ring-13C6) sodium salt 4.5-hydrate, batch SZBB264XV, purity 99.9%, 
expiry date September 21, 2014, Sigma Aldrich, MO (USA). 
 
2.1.2 Materials and reagents 
Ethyl acetate for trace analysis (Carlo Erba Reactifs-SDS). 
Methanol, code 701091.1612, (LC-MS) PAI, Panreac Quimica, Barcelona (Spain). 
MilliQ water obtained from a MilliQ water system, Millipore, Bedford, MA (USA). 
Ammonium acetate 99.99+%, code 431311, Sigma Aldrich, MO (USA). 
Acetonitrile, code 701881.1612, (LC-MS) PAI, Panreac Quimica, Barcelona (Spain). 
Acetic acid, code 07692, TraceSelectUltra for trace analysis, Sigma Aldrich, MO (USA). 
Ammonium hydroxide, 28% in water, 99.99 metals basis, code 338818, Sigma Aldrich, 
Germany. 
OASIS HLB cartridges 6CC (0.2 g), code WAT106202, Waters, Milford, MA, USA. 
 
2.1.3 Reagent solutions 
Mobile phase A: 5 mM ammonium acetate  
a. Weigh 0.385 g of ammonium acetate in a 1-l volumetric flask. 
b. Dissolve and dilute to volume with water. 
 
Mobile phase B: methanol;acetonitrile 50;50, % v/v 
a. Transfer 500 ml of methanol and 500 ml of acetonitrile into a 1-l bottle. 
b. Mix and degas in ultrasonic bath for 20 seconds. 
 
UHPLC Autosampler strong washing solution 
a. Transfer 900 ml of water, 47.5 ml of methanol, 47.5 ml of acetonitrile, and 5 ml of 
glacial acetic acid into a 1-l bottle. 
b. Mix and degas in ultrasonic bath for 20 seconds. 
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UHPLC Autosampler weak washing solution 
a. Transfer 45 ml of water, 475 ml of methanol, 475 ml of acetonitrile, and 5 ml of 
glacial acetic acid into a 1-l bottle. 
b. Mix and degas in ultrasonic bath for 20 seconds. 
 
UHPLC Seal washing solution 
a. Transfer 100 ml methanol and 900 ml of water into a 1-l bottle. 
b. Mix and degas in ultrasonic bath for 20 seconds. 
 
UHPLC-MS/MS Reconstituting solution for LC-MS/MS analysis 
a. Transfer 900 ml of mobile phase A into a 1-l bottle. 
b. Add 100 ml of mobile phase B and mix. 
 
2.1.4 Standard solutions 
Diclofenac stock standard solution (970 µg/ml) 
a. Accurately weigh approximately 9.7 mg of diclofenac in a 10-ml volumetric flask. 
b. Dissolve and dilute to volume with methanol and mix. 
 
Intermediate Standard Solution 1 (970 ng/ml) 
a. Transfer 10 µl of diclofenac stock standard solutions (970 µg/ml) into a 10-ml 
volumetric flask. 
b. Dilute to volume with methanol and mix. 
 
Intermediate Standard Solution 2 (9.7 ng/ml) 
a. Transfer 100 µl of diclofenac intermediate standard solution 1 (970 ng/ml) into a 10-ml 
volumetric flask. 
b. Dilute to volume with methanol and mix. 
 
Standard Solution A (0.194 ng/ml) 
a. Transfer 20 µl of intermediate standard solution 2 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50, (%, v/v) and mix. 
 
Standard Solution B (0.97 ng/ml) 
a. Transfer 100 µl of intermediate standard solution 2 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50, (%, v/v) and mix. 
 
Standard Solution C (1.94 ng/ml) 
a. Transfer 200 µl of intermediate standard solution 2 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50, (%, v/v) and mix. 
 
Standard Solution D (38.8 ng/ml) 
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a. Transfer 40 µl of intermediate standard solution 1 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50 (%, v/v), and mix. 
 
Standard Solution E (97 ng/ml) 
a. Transfer 100 µl of intermediate standard solution 1 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50 (%, v/v), and mix. 
 
Standard Solution Low QC (2.91 ng/ml) 
a. Transfer 0.3 ml of intermediate standard solution 2 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50 (%, v/v), and mix. 
 
Standard Solution High QC (87.3 ng/ml) 
a. Transfer 90 µl of intermediate standard solution 1 into a 1-ml dark vial. 
b. Dilute to 1 ml with acetone:hexane 50:50 (%, v/v), and mix. 
 
2.1.5 Internal standard solutions 
Internal standard stock solution (diclofenac 13C6, 10 mg/ml) 
a. Accurately weigh approximately 10 mg of diclofenac 13C6 and dissolve them in 1 ml of 
methanol. 
 
Internal standard working solution 1 (diclofenac 13C6 ,10 µg/ml) 
a. Transfer 10 µl of diclofenac 13C6 10 mg/ml into a 10-ml volumetric flask. 
b. Dilute to 10 ml with methanol and mix. 
 
Internal standard working solution 2 (diclofenac 13C6 ,1 µg/ml) 
a. Transfer 1 ml of Internal Standard working solution 1 (10 µg/ml) into a 10-ml volumetric 
flask. 
b. Dilute to 10 ml with methanol and mix. 
 
2.2 Apparatus 
2.2.1 Laboratory equipment 
Analytical balance:  Model AX204, Mettler-Toledo SpA 
Automatic pipettes:  Eppendorf research (Milan, Italy) 
Microsyringes:  Microliter Syringes, Hamilton (Reno, CA, USA) 
Autosampler vials for LC-MS: Micro-V vials target Dp clear, 1.5 ml, 12x22 mm National 
Scientific (Germany) 
Volumetric flasks:  Grade A various sizes, Duran® 
Volumetric pipettes:  Grade A various sizes, Duran® 
Dionex Autotrace AT280 automated SPE system (Thermo Scientific, Waltham, MA, USA) 
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TurboVap II (Caliper Life Science, Mountain View, CA, USA) 
Vortex Genius, Ika, Staufen, Germany 
 
 
2.2.2 Instrumental equipment and conditions 
2.2.2.1  UHPLC equipment and conditions  
Pumps: Binary Solvent Manager, Model UPB, Waters (Milford, MA, USA) 
Autosampler: Sample Manager, Model UPA, Waters (Milford, MA, USA) 
Detector: QTRAP 5500, Applied Biosystems MDS SCIEX, (Foster City, CA, USA) 
equipped with Turbo V™ ion source 
Flow rate: 400 µl/min  
Injection volume: 5 µl 
Analytical column: Triart C18, 1.9 µm, 50 x 2.1 mm, YMC (Dinslaken, Germany) equipped 
with UHPLC column saver (Fortis, Technologies) 
Mobile phase A: 5 mM ammonium acetate  
Mobile phase B: Acetonitrile-methanol (50:50, % v/v) 
 
The chromatography was performed in gradient mode according to the following scheme: 
 
Time  A B Flow (ml/min) 
0 90 10 0.4 
1 90 10 0.4 
9 5 95 0.4 
9.1 5 95 0.4 
9.2 90 10 0.4 
12 90 10 0.4 
Under these conditions, the retention time of diclofenac was about 6.2 minutes. The run time 
was 12.5 minutes. 
2.2.2.2  QTRAP 5500 operative condition  
An AB Sciex QTRAP5500 mass spectrometer equipped with Turbo V™ ion source was used. 
The instrument was previously tuned and calibrated in electrospray mode using 
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polypropylene glycol (PPG). Prior to analysis, all the specific parameters were optimised 
infusing a 1 µg/ml standard solution of analyte and internal standard (IS).  
The eluent from the column was introduced directly into the ion source. The rapid 
desolvation and vaporisation of the droplets minimises thermal decomposition and preserves 
their molecular identity. The data were collected using the software programme Analyst 1.6. 
All calculations were based on chromatographic peak area ratios for the multiple reaction 
monitoring (MRM) precursor-product ion transitions for analyte to the precursor-product ion 
transition of the internla standard. The general operating conditions were as follows: 
Scan Type:  Scheduled MRM 
Polarity:  Negative  
Ion Source:  Turbo Spray 
Resolution Q1:  Unit 
Resolution Q3:  Unit 
MR Pause:  5.0000 msec 
 
 
Analyte MRM Time(min) Declustering Potential 
(DP) 
Collision Energy 
(CE) 
Diclofenac 
(294>250) 
6.2 -42 -16 
Diclofenac 
(294>214) 
6.2 -42 -29 
 
 
Curtain gas (CUR):     25 
Collision gas (CAD):     Medium 
Temperature (TEM):     550 
Ion Transfer Voltage (IS):    -4 500. 
Entrance Potential (EP) -   10.00 
Collision cell Exit Potential (CXP)  -11.00 
Ion Source gas 1 (GS1)   55 
Ion Source gas 2 (GS2)   45 
3 Experimental set up of method validation  
Different experiments were carried out for the characterisation of the developed procedure in 
terms of limit of detection and quantitation, linearity and working range, recovery, trueness, 
repeatability, intermediate precision and sample and extract stability. In our approach, a 
calibration curve and quality controlled samples (QCs) were freshly prepared in triplicate for 
five different days. Some of the experiments were used in the evaluation of different 
parameters.  
The analyte / internal standard peak area ratios will be used as target parameters for 
quantitation. A weighted (1/c) least-square regression analysis of data was performed to 
determine the calibration curve parameters and the coefficient of determination (R2). 
The equation obtained with the linear regression method is as follows: 
X = 
A
BY 
 
where: 
WATCH LIST SUBSTANCE: DICLOFENAC – MONITORING METHOD 
 
17/11/2014  13 of 24 Pages 
 
X = analyte concentration 
Y = peak area ratio = 
areapeak  I .S.
areapeak    analyte 
 
A = slope  
B = intercept 
Analyst 1.6 software was used for data acquisition and data processing.  
Statistical calculations will be performed using Excel software. 
 
3.1 Calibration curve 
Calibration standards in MillliQ water (six different spiking levels, including a blank sample) 
covering the studied calibration range (0.2-97 ng/l) were freshly prepared and processed on 
each day of validation. 
The relationship (goodness of fit) between peak area ratios of analyte / I.S. and 
concentrations in the investigated concentration range was assessed by the coefficient of 
determination (R2) and by the shape of the distribution of residuals around the horizontal 
axis. 
The acceptance criteria set for calibration curves were: 
 R2  0.9900 calculated over five calibration curves and  
 random dispersion of residuals around the horizontal axis, proving the pertinence of 
the linear regression model to interpret the data. 
3.2 Repeatability and intermediate precision 
Quality controlled samples (QCs) were freshly prepared in MilliQ water and analysed in 
triplicate during validation days at two spiking levels (2.91 and 87.3 ng/l) for a total of 15 
independent sample preparations. 
The acceptance criterion set for the relative standard deviation (RSD) of the repeatability 
and intermediate precision was 15% at both spiking levels.  
3.3 Limits of detection and quantification  
The limits of detection and quantification were estimated by analysing 15 different blank 
samples. 
The mean value of blank samples (b) and the RSD served for LOD and LOQ estimation, in 
accordance with the following equations: 
LOD = b + 3SD 
LOQ = b + 10SD. 
3.4 Trueness 
Trueness was assessed by analysing 15 different QCs at each spiking level and by the 
application of the significance test (t-test) at the 95% confident level. The difference 
between the mean value of spiked MilliQ water samples and their nominal concentration was 
evaluated according to the following formula:  
 
where (x) is the mean value of (n) samples with standard deviation (SD), and (µ) is the 
nominal concentration.  
3.5 Recovery 
Recovery was evaluated by extracting and analysing in triplicate 1-litre MilliQ water samples 
spiked, before extraction, with native analytes only. The internal standard was then added to 
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the extracts at the end of the sample preparation with the aim of allowing the estimation of 
analyte loss during processing. 
The recovery was evaluated by comparing the ratios analyte/IS in spiked samples to the 
same ratios obtained by analysing a standard solution containing native compounds and the 
labelled solution at the same concentration levels, not subject to any handling.  
The spiking level was 9.7 ng/l. 
3.6 Stability  
3.6.1 Stability of extract  
Three extracts of QC at each spiking level were re-injected after storage at 4°C for one week 
in the dark. In order to be considered stable, the concentration of re-injected samples had to 
fall within about twice the standard deviations of the concentration of QCs used for the 
repeatability study. 
3.6.2 Stability of sample  
The stability of the analyte in water samples during storage was studied by analysing low 
and high QCs, prepared on 3 August 2012 and stored under identical temperature and 
lighting conditions to those of the real water samples (i.e. 5˚C, in darkness).  
Stability samples for diclofenac were extracted and analysed on days 0, 38, 83 and 96 after 
spiking. 
Concentrations in samples had to fall within twice the standard deviation of the 
concentrations of QCs used for repeatability evaluation.  
4 Preparation of calibration standards and water samples  
4.1 Calibration standards and Quality Control samples (QCs) 
a. Fill 1-l glass bottle with 1 l MilliQ water. 
b. Add 1 ml of working standard solution according to the following: 
 
Standard 
solution 
Diclofenac  
concentration 
ng/ml 
Diclofenac 
concentration 
in water 
ng/l 
 IS 
concentration 
in water 
(ng/l) 
A 0.19 0.19 Calibration 
samples 
10 
B 0.97 0.97 „ 10 
C 1.94 1.94 „ 10 
D 38.8 38.8 „ 10 
E 97 97 „ 10 
Low QC 2.91 2.91 QC samples 10 
High QC 87.3 87.3 „ 10 
 
4.2 Water sample extraction  
a. Add 10 µl of diclofenac 13C6 working solution 2 to 1 l water standard and QC samples 
b. Shake the water sample 
c. Condition SPE OASIS HLB cartridge with 10 ml of ethyl acetate 
d. Condition SPE cartridge with 10 ml of methanol 
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e. Condition SPE cartridge with 10 ml of water 
f. Load water samples at 10 ml/minute 
g. Dry the sorbent under nitrogen for 30 minutes 
h. Elute the sample with 10 ml ethyl acetate at 5 ml/minute. 
 
Half of the extract (i.e. about 5 ml) evaporated due to dryness and was reconstituted in 0.2 
ml of reconstituting solution for LC-MS/MS analysis.  
5 Validation procedure and results 
 
5.1 Selectivity 
For the identification of diclofenac, two multiple reaction monitoring (MRM) transitions 
between the precursor ion and the two most abundant fragment ions were monitored. The 
first was used for quantification purposes, whereas the second (“qualifier”) was used to 
confirm the presence of the target compound in the sample. The quantified analyte was 
identified by comparing the retention time of the corresponding standard and the isotopic 
ratio between two ions recorded (±30%), in the standard and water samples. 
The selected mass transitions used for quantification were 294 > 250 for diclofenac, and 300 
> 256 for diclofenac 13C6. 
 
5.2 Limit of detection (LOD) and limit of quantification (LOQ) 
Limits of detection and quantification were estimated by analysing blank samples.  
A typical blank chromatogram is depicted in Figure 1. 
 
Figure 1 – Chromatogram of a blank sample 
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The mean values of the blank samples (b) and standard deviation (SD) were calculated using 
the data resulting from these experiments. LOD and LOQ were estimated according to the 
formula reported in 3.3. 
The results of the LOD and LOQ estimation are shown in Table 1. 
 
Table 1 - LOD and LOQ values 
Analyte Nr of 
blanks 
analysed 
LOD 
(ng/l) 
LOQ 
(ng/l) 
Diclofenac 15 0.1 0.2 
 
5.3 Linearity study 
The linearity of the whole SPE-LC-MS-MS procedure was studied in the concentration range 
0.19-97 ng/l. 
In order to verify the linearity of the calibration curve, a blank sample spiked only with 
labelled IS and five spiked MilliQ water samples (i.e.: 0, 0.19, 0.97, 1.94, 38.8, 97 ng/l) 
were extracted and analysed in three replicates on five different days. The calibration curves 
are illustrated in Figure 2. 
Figure 2 – Calibration curves 
 
 
As reported in Table 2, the mean coefficient of determination (R2) values, calculated over 
five calibration curves, was ≥0.994, with an RSD of 0.7 %. 
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Table 2 - Coefficient of determination (R2) values for calibration curves on different days 
Validation Day R2 
1 0.9979  
2 0.9976  
3 0.9965  
4 0.9965  
5 0.9815  
Average 0.994 
RSD (%) 0.7 
The study of the distribution of residuals revealed shapes randomly dispersed around the 
horizontal axis, proving the pertinence of the linear regression model for interpreting the 
data. The residual plots are shown in Figure 3. 
Figure 3 – Residual plots 
 
 
5.4 Working Range 
The working range, defined as the range of concentrations for which the chosen calibration 
curve is valid, was defined by the limits of quantification and highest point in the respective 
calibration curve. Table 3 summarises the working range established for the procedure. 
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Table 3 - Working range of the analytical method 
Analyte Working range (ng/l) 
Diclofenac 0.2-97.3 
 
5.5 Trueness 
Fifteen QCs at low and high concentration levels (i.e. about 3 and 90 ng/l) were extracted 
and analysed, and the back-calculated concentrations were evaluated to demonstrate the 
truthfulness of the null hypothesis (H0: the analytical method is not subject to systematic 
error). 
As reported in Table 4, the t-values were found to be lower than the critical values for the 
target analyte at the studied concentration levels, demonstrating the absence of evidence of 
systematic errors in analyte quantification. 
 
Table 4 - Results of the trueness study at the different concentration levels 
Analyte Mean 
value 
(x) 
ng/l 
Nr of 
samples 
(n) 
Nr of 
degrees 
of 
freedom 
Theoretical 
value (µ) 
ng/l 
Standard 
Equation 
of 
samples 
(SD) ng/l 
Calculated 
t-value 
Critical 
t₄ 
P=0.05 
Decision 
Diclofenac 2.94 15 10 2.91 0.41 0.29 2.23 OK 
88.4 15 10 87.3 7.3 0.59 2.23 OK 
 
5.6 Recovery 
The results of the recovery experiments, carried out according to section 3.5, are reported in 
Table 5. 
Table 5 - Recovery 
Analyte Spike Level  
(ng/l) 
Mean Recovery  
(%) (n=3) 
SD (ng/l) RSD (%) 
Diclofenac 9.7 71.2 3.61 5.1 
 
5.7 Repeatability and intermediate precision 
For repeatability and intermediate precision, QCs at two concentration levels were tested on 
five different days. For each sample, three replicate injections were made. Using one-way 
ANOVA, the results were obtained as shown in Table 6. 
Table 6 – Relative standard deviations of repeatability and intermediate precision  
Concentration 
level 
Relative standard deviation (RSDRep) of 
Repeatability measurements 
Relative standard deviation (RSDIp) of 
Intermediate precision measurements 
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Low 2.6 14.6 
High 3.1 8.2 
 
5.8 Stability 
5.8.1 Stability of extract  
A graphical representation of the stability of extracted data is reported in Figure 4.  
Since the concentrations evaluated by reinjections after storage for one week at 4°C in the 
dark fall within about twice the standard deviations of the concentration of QCs used for 
repeatability evaluation, the extracts could be considered as being stable in the studied 
conditions. 
 Figure 4 – Stability of extract after one week storage at 4°C in the dark 
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5.8.2 Stability of water samples 
A graphical representation of stability data of diclofenac in water samples is reported in 
Figure 5. 
Since the concentrations in stability samples fall within about twice the standard deviation of 
the concentrations of quality control samples used for repeatability evaluation, the samples 
could be considered stable. 
Figure 5 – Stability of water samples 
 
 
 
 
 
 
5.9 Uncertainty estimation 
The estimation of measurement uncertainty was carried out following a top-down approach 
based on in-house validation data. The data derived from the validation of the method 
includes the sample preparation, standard dilution, and chromatographic and MS detection 
variability. This approach takes account of the relative standard deviation of repeatability, 
intermediate precision and trueness measurements. The uncertainty of prepared standard 
stock solution is also considered, as another source of uncertainty.  
The expanded uncertainty was calculated using the following formula: 
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, where: 
 
U is the expanded relative uncertainty,  
k is the coverage factor (k=2), 
 is the relative standard uncertainty of trueness estimation,  
uRep is the relative standard uncertainty of repeatability, 
 is the relative  standard uncertainty of intermediate precision and  
uStd is the relative standard uncertainty related to calibration standards including weighing, 
purity and dilution contributions.  
 
5.9.1 Uncertainty of trueness 
uTness is the standard relative uncertainty associated with the trueness, and has been 
calculated from the standard deviation (SD) of the mean of QCs used for trueness as follows: 
, where:  
C is the average result of the QCs analyses,  
n is the number of QCs that have been analysed. 
 
5.9.2 Uncertainty of repeatability and intermediate precision  
 and   are the standard relative uncertainties related to repeatability and intermediate 
precision measurements, respectively. Individual contributions are calculated according to 
the following equations: 
 
and  
, where: 
RSDRep standard deviation of repeatability measurements  
RSDIp standard deviation of intermediate precision measurements 
n Rep number of total replicates for repeatability measurements 
n days number of days for intermediate precision measurements. 
 
5.9.3 Uncertainty of standard 
 is the standard relative uncertainty associated with diclofenac and diclofenac 13C6 
standards used, and is calculated as follows: 
, where: 
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uDiclofenac is the uncertainty relative to the diclofenac standard used in the calibration solution 
preparation. The Manufacturer’s Certificate of Analysis reports the UDiclofenac as having an 
expanded combined uncertainty at 95% confidence level equal to 0.5%. Consequently:  
udiclofenac=Udiclofenac/2 = 0.25. 
uIS is the uncertainty relative to the diclofenac 
13C6 standard used as internal standard. 
The Manufacturer’s Certificate of Analysis reports the UIS, as expanded combined uncertainty 
at 95% confidence level, with n=6, equal to ±0.5%. Consequently, the relative uncertainty is 
0.2, according to the following formula:  
udiclofenac 
13
C6=Udiclofenac
13
C6/2.45 = 0.2 
uFlask is the uncertainty related to the volumetric flask. The tolerance of the class A 10-ml 
volumetric flask (given by the manufacturer) is set to 0.04 ml. As this value is not correlated 
with a confidence level or distribution information, a rectangular distribution is assumed. For 
the uncertainty estimation, the relative tolerance value (i.e. 0.4%) must by divided by , 
giving a value of 0.231 for uFlask. 
 
uSyringe is the uncertainty related to the withdrawal of the standard solution using a 1 000-µL 
Hamilton syringe. As these syringes are manufactured to be accurate within ± 1% of the 
nominal value and this value is not correlated with a confidence level or distribution 
information, a rectangular distribution is assumed. For the uncertainty estimation the relative 
uncertainty (i.e. 1 ml/1 000 ml*100=0.1%) must by divided by , giving a value for uSyringe 
equal to 0.058. 
 
uBalance is the contribution from the weight of standards, and it is due to the linearity 
uncertainty of the balance from Calibration Certificate. From balance linearity (± 0.03 mg), a 
rectangular distribution is assumed to obtain a standard uncertainty; this contribution is 
considered twice, once for the tare and once for the gross weight. According to this 
approach, the uBalance as RSD % is: 
uBalance= =0.02 
 
uBalance=  = 0.2%. 
 
As the repeatability and trueness of the measurement were estimated for two different 
concentration levels, the uncertainty can also be estimated separately for low and high 
concentration levels. 
 
5.10 Final uncertainty budget  
The dominating uncertainty contribution came from the trueness assessment, which was 6.5 
and 3.7% at low and high concentration levels respectively. The other uncertainty 
contributions from repeatability, trueness and standard preparation were around 1%.   
The expanded relative uncertainty was estimated as 13 and 8% at low and high 
concentration levels respectively, based on 15 replicate measurements on 5 days, and as 30 
and 18% for a single measurement performed on a single day. 
The detailed uncertainty budget and results of the uncertainty estimations are reported in 
Table 7. 
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Table 7 - Uncertainty budget and estimated uncertainty of measurements 
Estimated uncertainty Values 
 Low concentration 
level 
(2.91 ng/l) 
High concentration 
level 
(87.3 ng/l) 
uTness (%) 0.5 1.5 
uRep (%) 0.7 0.8 
uIp (%) 6.5 3.7 
uStd (%) 0.5 0.5 
Expanded Relative Uncertainty  
(U, %)) (k=2), (n1=15, n2=5) 
13 8 
Expanded Relative Uncertainty  
(U, %) (k=2), (n1=1, n2=1) 
30 18 
 
5.11 Remark on LoQ 
As regards the afore-described method it has to be annotated that in 2013, the French 
standardisation body AFNOR, has published a standard for the analysis of medical waste 
products, i.e. XP T90-223: Water quality - Determination of Some drug residues in the 
water-Dissolved fraction - Method using solid-phase extraction (SPE) and liquid 
chromatography tandem mass spectrometric analysis with investigation (LC-MS / MS). In 
addition to that the French Reference Laboraratory for Water (AQUAREF) has test in two 
intercomparison exercises in 2009 and 2012, respectively, a method available on the website 
AQUAREF (http://www.aquaref.fr/system/files/Fiche%20MA14-230309%20.pdf). 
While both methods feature similar results in terms of extraction recovery, differences can 
be observed with regard to the limits of quantification. 
This may be ascribed to the different water matrices used (artificial mixtures in case of the 
method described above vs. processed real water samples). In addition, the approach used 
to evaluate the limit of quantification is different form the procedures applied in France. 
However, in both scenarios, the LOQs of the methods meet the requirements for the 
implementation of a watch list monitoring, i.e.10 ng/l vs. 0.2 ng/l. 
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